Adjuvant Therapy With Anlotinib for HCC

NCT04947371 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The standard of care of adjuvant therapy for liver cancer was changed.

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Anlotinib Hydrochloride

Sponsor

Shanghai Zhongshan Hospital